Changes in brain ¹¹C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET

Author： Kadir Ahmadul Darreh-Shori Taher Almkvist Ove Wall Anders Långström Bengt Nordberg Agneta

Publisher： Springer Publishing Company

ISSN： 0033-3158

Source： Psychopharmacology, Vol.191, Iss.4, 2007-05, pp. : 1005-1014

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

PET imaging of cortical ¹¹C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease

By Kadir Ahmadul Almkvist Ove Wall Anders Långström Bengt Nordberg Agneta

Psychopharmacology, Vol. 188, Iss. 4, 2006-11 ,pp. : 509-520

Springer Publishing Company

Access to resources Recommend Favorite

Risk of Antipsychotic Drug Use in Patients with Alzheimers Disease Treated with Rivastigmine

By Suh D-C.

Drugs & Aging, Vol. 21, Iss. 6, 2004-01 ,pp. : 395-403

Adis International

Access to resources Recommend Favorite

Long-Term Effects of Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimers Disease: Results of a 52-Week Open-Label Study

By Edwards Keith

Clinical Drug Investigation, Vol. 25, Iss. 8, 2005-01 ,pp. : 507-515

Adis International

Access to resources Recommend Favorite

Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimers Type

By Hossain M.

Clinical Pharmacokinetics, Vol. 41, Iss. 3, 2002-01 ,pp. : 225-234

Adis International

Access to resources Recommend Favorite

Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status

By Gottwald M.D. Rozanski R.I.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1673-1682

Informa Healthcare

Access to resources Recommend Favorite